ADRB3 and major depressive disorder: Together with the findings in non-social stress animal models [30], the evidence supports the idea that pharmacologically targeting the beta-3 adrenoceptors holds potential for developing novel antidepressants for depression treatment, which is achieved by promoting resilience-like phenotypes in chronic stress models of depression.